Kailera Therapeutics has completed enrollment of approximately 4,900 adults across three Phase 3 trials of once-weekly ribupatide injection for obesity and overweight, with dosing to 10 mg over 76 weeks. One trial measures weight loss directly against semaglutide 2.4 mg, and another tracks hemoglobin A1c in participants with type 2 diabetes. Topline data are expected in mid-2028.
Key Points
- Three Phase 3 trials enrolled roughly 4,900 adults, 11 countries
- KaiNETIC-3 compares ribupatide head-to-head against semaglutide 2.4 mg
- 76-week dosing to 10 mg; topline results mid-2028
Longevity Analysis
Pharmacological weight reduction now operates on metabolic terrain that extends well past body mass — insulin signaling, inflammatory load, cardiac workload, and joint mechanics all shift with sustained adiposity loss. A head-to-head comparison against semaglutide moves the field from asking whether these agents work to asking which produces the most durable metabolic repair at tolerable cost, including preservation of lean mass and nutrient status over 76 weeks of exposure. For anyone considering these compounds, the decisive variables remain what else is driving the metabolic dysfunction, how the body signals satiety and energy availability once appetite is pharmacologically suppressed, and whether the behavioral architecture exists to hold the result.
Original published by Longevity.Technology.